Shots:

• Neuclone plans for the onset of P-I clinical study for NeuLara- a Stelara's biosimilar evaluating NeuLara vs the US & EU score of Stelara in healthy candidates in Australia under CTN scheme of TGA in H2'19
• NeuLara is developed utilizing NeuMAX technology & Right from the Start development approach- analytically tested with X-ray crystallography for the confirmation of the identical structure b/w NeuLara and Stelara
• J&J's Stelara (ustekinumab) is a mAb targeting IL-12 and IL-23- approved for moderate to severe plaque psoriasis in adults and children aged ≥12yrs and has generated $5.2B revenue in 2018. NeuLara X-ray Crystallography is technique allowing 3-D imagining of complex molecules

Click here to read full press release/ article | Ref: PRNewsWire | Image: NeuClone